Nebulized inhalers for the treatment of respiratory diseases

A technology for respiratory diseases and aerosol inhalation, which is applied in the field of pharmaceutical preparations, can solve the problems of shortening the clearance time of saccharin, achieve good compliance, avoid damage and degradation, and have high bioavailability

Active Publication Date: 2017-10-10
BEIJING GRAND JOHAUM PHARMA CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Han et al. studied the effect of mucus regulators on human nasal MCS, and found that after 10 days of oral administration of extracts containing eucalyptol, limonene and pinene, the clearance time of saccharin was significantly shortened compared with that before administration, but human nasal mucosa in vitro cultured in the incubation solution No significant change in ciliary movement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nebulized inhalers for the treatment of respiratory diseases
  • Nebulized inhalers for the treatment of respiratory diseases
  • Nebulized inhalers for the treatment of respiratory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039]

[0040]

[0041] Preparation method: mix the raw materials with polyoxyethylene sorbitan monooleate, polyoxyethylene hydrogenated castor oil and poloxamer 407, add water for injection with 80% of the prescription amount and add sodium chloride, stir to make the solution clear, Add water to make the volume to 1000ml, filter the medicinal solution with a 0.22μ microporous membrane, and distribute it into suitable aerosol vials.

[0042] The quality of the atomized inhalation that present embodiment makes is as follows:

[0043] 1. Properties: transparent liquid.

[0044] 2. Identification:

[0045] 2.1 Take 1ml of this product, add a few drops of p-dimethylaminobenzaldehyde test solution, the solution is light red

[0046] 2.2 In the gas chromatogram obtained under the content determination of this product, the retention times of the three main peaks of the test solution are consistent with those of the reference substance peaks of eucalyptol, limonene and pinene...

Embodiment 2

[0054]

[0055] Preparation method: mix polyoxyethylene hydrogenated castor oil and polyoxyethylene sorbitan monooleate, add eucalyptol, limonene and pinene, heat and stir in a closed environment, add 70% of the prescription amount of normal saline and high-pressure homogenate to dissolve into To clarify the solution, add potassium dihydrogen phosphate and sodium hydroxide solution to adjust the pH to 7.0, and add physiological saline to make the volume to 1000ml. The medicinal solution is filtered with a 0.22μ microporous membrane, and distributed into suitable aerosol vials.

[0056] The quality of the atomized inhalation prepared in this embodiment is substantially the same as that of the atomized inhaler prepared in Example 1.

Embodiment 3

[0058]

[0059] Preparation method: pass the solid excipients through 80 mesh sieve for later use, dissolve eucalyptol, limonene and pinene into poloxamer 407 and polyoxyethylene sorbitan monooleate, stir and mix under vacuum for 20 minutes, add the prescription amount Stir 70% normal saline for 5 minutes and perform high-pressure homogenization twice, add vitamin C and carbomer, add potassium dihydrogen phosphate and disodium hydrogen phosphate to adjust the pH to 7.0, and adjust the volume of normal saline to 1000ml. The medicinal solution is filtered with a 0.22μ microporous membrane, and distributed into suitable aerosol vials.

[0060] The quality of the atomized inhalation prepared in this embodiment is substantially the same as that of the atomized inhaler prepared in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
refractive indexaaaaaaaaaa
Login to view more

Abstract

The invention provides a nebulizer for treating respiratory system diseases. The nebulizer contains (A) 0.1-20 g / L of terpenoid, (B) 0.1-20 g / L of a non-ionic surfactant, and (C) 0.1-20 g / L of an osmotic pressure regulator. The nebulizer can form medicinal steam, mist or aerosol through a sprayer or an atomizer and the like, and is inhaled by the respiratory tract or locally sprayed. The nebulizer has the following advantages that 1, the target is directly arrived, the response is quick, and local action or general action can be exerted; 2, the first-pass effect of the liver and the destroying and degradation of gastrointestinal tracts can be avoided, and the bioavailability is high; 3, the nebulizer has good compliance.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to an atomized inhaler for treating respiratory diseases, more specifically, a drug vapor, mist or gaseous drug formed by a nebulizer or an atomizer for treating respiratory diseases. Sol. Background technique [0002] Chronic rhinosinusitis is a clinical frequently-occurring disease in otolaryngology, and its etiology is complex, mainly including pathogenic microorganism infection, abnormal intranasal anatomy, immune deficiency, mucociliary dysfunction, and allergic reaction. The pathological changes are mainly manifested as inflammatory lesions of the airway mucosa, which can cause damage to the mucociliary clearance system (MCS). The mucociliary clearance system excretes inhaled dust, bacteria and other harmful substances through the cilia transport function, and is an important mechanical protective barrier of the human respiratory tract. When its function is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/35A61K9/12A61K9/72A61P11/02A61P11/00A61P11/08A61P31/10A61P31/06A61P29/00A61K31/015
Inventor 黄志武赵家欣汤文清
Owner BEIJING GRAND JOHAUM PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap